Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ELV stock price vs FAST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FAST's multiple
Needs FAST P/E.
Implied fair value · at ELV's multiple
Needs ELV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Elevance Health, Inc. · implied price per share
Bear
$158.07
Base
$203.66
Bull
$263.02
FASTENAL CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UnitedHealth Group Incorporated
ELV vs UNH
CVS Health Corporation
ELV vs CVS
HUMANA INC
ELV vs HUM
CENTENE CORP
ELV vs CNC
MSC INDUSTRIAL DIRECT CO INC
ELV vs MSM
APPLIED INDUSTRIAL TECHNOLOGIES INC
ELV vs AIT
HOME DEPOT, INC.
ELV vs HD
LOWES COMPANIES INC
ELV vs LOW
W.W. GRAINGER, INC.
ELV vs GWW
WESCO INTERNATIONAL INC
ELV vs WCC
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ELV can sustain its 12.5% revenue growth while improving margins toward FAST’s level, then ELV looks attractive because it trades at 15.2x P/E and 0.4x P/S versus FAST’s much richer 44.1x and 6.7x multiples; otherwise, the current discount may be justified by ELV’s far lower profitability and ROIC.
ELV trades at a sharp discount to FAST on both earnings and sales multiples, which mathematically supports a much higher implied price if ELV were valued like FAST. However, the gap is partly explained by FAST’s far stronger margins and ROIC, so the valuation spread reflects quality differences as well as market mispricing.
Supporting Metrics
